Currax Pharmaceuticals

What Currax Pharmaceuticals does

Currax Pharmaceuticals LLC is a privately held specialty pharmaceutical company headquartered in Brentwood, Tennessee, that acquires and commercializes branded and generic prescription drugs targeting chronic progressive diseases, with a primary focus on obesity, migraine, and sleep disorders. The company's flagship product, CONTRAVE (naltrexone HCl/bupropion HCl), is an extended-release fixed-dose combination and the only FDA-approved medication in the Reward System Regulator (RSR) class; it is the #1 branded oral weight loss medication in the United States and is marketed as MYSIMBA in the European Union and European Economic Area. Supporting products include ONZETRA Xsail (sumatriptan nasal powder) and TREXIMET (sumatriptan/naproxen sodium) for migraines and SILENOR (doxepin) for insomnia, alongside a Phase 1 pipeline of obesity candidates (CR-101-1, CR-101-2, CT-101, CM-101, CX-101, QDC-101).

The company's revenue model centers on prescription pharmaceutical product sales, augmented by a multi-channel direct-to-patient access infrastructure. CONTRAVE is sold at a $99/month cash price through the proprietary CurAccess Program, at $199/month through a GoodRx partnership spanning 70,000+ U.S. pharmacies, and via direct employer contracts through PeekDirect for self-funded plans, in addition to traditional prescription fulfillment. Commercial reach extends to over 50 countries, with global demand exceeding 2.2 million units in 2024 and CONTRAVE/MYSIMBA delivering greater than 50% year-over-year revenue growth for the second consecutive year. The company is investing in clinical evidence generation (the INFORMUS Cardiovascular Outcomes Trial targeting 8,600 patients), supply chain expansion (a second FDA-approved manufacturing site that more than doubles capacity), and a national CTV and digital direct-to-consumer campaign reaching over 70% of the U.S. population. The U.S. field force was expanded by approximately 25% in Q1 2025, and the company achieved positive EBITDA in 2024.

Name

Currax Pharmaceuticals

Legal name

Currax Pharmaceuticals LLC

Website

https://curraxpharma.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

101–250 employees

Short description

Currax Pharmaceuticals is a private specialty pharmaceutical company that acquires and commercializes branded prescription drugs, with its lead product CONTRAVE serving as the #1 branded oral weight loss medication in the U.S. for adults with obesity.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals (Obesity, Migraine, Sleep)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG), Lead Optimization & Preclinical Candidate Selection (HLAIALAB)

Keywords

• Specialty pharmaceuticals
• Weight management medication
• Migraine treatment drugs
• Insomnia therapy
• Branded generic drugs

Headquarters

HQ city

Morristown

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Marketing or Sales, Personnel, Supply Chain, Technology or R&D

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from the sale of branded and generic pharmaceutical products. CONTRAVE/MYSIMBA drove over 50% year-over-year revenue growth for the second consecutive year in 2024. Global demand reached over 2.2 million units in 2024.
2. International Product Sales: CONTRAVE is marketed as MYSIMBA in the European Union and European Economic Area, and is available in over 50 countries worldwide, contributing to international revenue streams.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

Currax Pharmaceuticals acquires and commercializes FDA-approved branded and generic prescription drugs for chronic progressive diseases. The lead product is CONTRAVE (naltrexone HCl/bupropion HCl), an oral extended-release medication for chronic weight management in adults with obesity or overweight with comorbidities. The portfolio also includes ONZETRA Xsail for migraine, TREXIMET for migraine, SILENOR for insomnia, and an authorized generic of TREXIMET, with CONTRAVE marketed internationally as MYSIMBA.

Product overview

Currax Pharmaceuticals is a specialty pharmaceutical company that offers a portfolio of branded and generic pharmaceutical products focused on addressing chronic progressive diseases, particularly obesity and smoking cessation. The core product portfolio includes CONTRAVE (naltrexone HCl/bupropion HCl) for obesity/weight management, ONZETRA Xsail for migraine treatment, SILENOR for insomnia, and TREXIMET for migraine relief, along with an authorized generic of Treximet. The company also maintains an active pipeline including CR-101-1, CR-101-2, CT-101, CM-101, CX-101, and QDC-101 in Phase 1 development for various obesity-related indications, and is conducting the INFORMUS cardiovascular outcomes trial for CONTRAVE.

Differentiator

Problem solved

Functional benefit

Brands

• CONTRAVE: FDA-approved obesity treatment (naltrexone HCl/bupropion HCl) - the #1 branded oral weight loss medication. Also marketed as MYSIMBA in Europe.
• ONZETRA Xsail
• SILENOR
• TREXIMET
• MYSIMBA
• CurAccess Program

Products and services

• CONTRAVE (naltrexone HCl/bupropion HCl) FDA-approved extended-release fixed-dose combination medication for chronic weight management in adults with obesity (BMI ≥30 kg/m2) or overweight adults (BMI ≥27 kg/m2) with at least one weight-related medical problem. Targets the brain's reward system to reduce hunger and control cravings. Targets individual adult patients with obesity or weight-related comorbidities.
• MYSIMBA (naltrexone HCl/bupropion HCl) International brand name for CONTRAVE, marketed in the European Union and European Economic Area and distributed in over 50 countries worldwide for chronic weight management.
• ONZETRA Xsail (sumatriptan nasal powder) Sumatriptan nasal powder delivered via breath-powered delivery system for acute treatment of migraine attacks in adult patients.
• TREXIMET (sumatriptan/naproxen sodium) Combination medication of sumatriptan and naproxen sodium for acute treatment of migraine attacks with or without aura in adult patients.
• SILENOR (doxepin) Doxepin medication for the treatment of insomnia characterized by difficulty with sleep maintenance in adult patients.
• CurAccess Program Direct-to-patient affordability program offering CONTRAVE at no more than $99 per month with free shipping to all patients with a CONTRAVE prescription, regardless of insurance coverage. Price has remained unchanged since 2019.

Quantifiable outcome

• 9.5% average weight loss at 56 weeks vs 2.7% for placebo (p<0.0001)
• +6 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• Peek Healthcare TechnologiescoreChannel Partner/ Reseller/ Distributor · 1 April 2026PeekDirect partnership connects self-funded employers and patients directly with Currax for transparent, upfront pricing of CONTRAVE. The program eliminates traditional rebate-driven intermediaries to deliver lower out-of-pocket costs while maintaining existing prescribing workflows. Partnership includes Professional Arts Specialty Pharmacy as dispensing pharmacy partner.
• GoodRxcoreChannel Partner/ Reseller/ Distributor · 15 July 2025GoodRx partnership provides cash pay prescription access to CONTRAVE at $199 via GoodRx, available at over 70,000 pharmacies nationwide. This collaboration expands access to affordable weight management medication for more patients regardless of insurance status.
• Life Science TennesseeminorStrategic or Co-development PartnerBusiness alliance partnership supporting the Tennessee life sciences ecosystem and industry collaboration.
• MercyminorStrategic or Co-development PartnerHealthcare system partnership for business development and healthcare innovation initiatives.
• Obesity Medicine Association (OMA)coreGTM or Marketing PartnerAdvocacy partnership supporting obesity care education and awareness. OMA co-developed the joint expert guidance statement that gave CONTRAVE its highest recommendation.
• Obesity Action Coalition (OAC)coreGTM or Marketing PartnerPatient advocacy partnership supporting obesity awareness and patient empowerment. OAC co-developed the joint expert guidance statement on pharmacological management.
• The Obesity Society (TOS)coreGTM or Marketing PartnerProfessional society partnership supporting obesity research and clinical practice guidelines. TOS co-developed the joint expert guidance statement giving CONTRAVE strong recommendation.
• STOP Obesity AllianceminorGTM or Marketing PartnerAdvocacy partnership working to eliminate obesity stigma and improve access to evidence-based treatment.
• American Medical Women's Association (AMWA)minorGTM or Marketing PartnerProfessional association partnership supporting women's health education and advocacy.
• European Association for the Study of Obesity (EASO)minorGTM or Marketing PartnerInternational professional organization partnership supporting obesity research and education in Europe.

Scale indicators8 records

Recent moves8 records

Expansion highlights8 records

Broad incumbents

• Novo Nordisk: Global leader in obesity and diabetes care with Wegovy (semaglutide) and Ozempic. Comparable to Currax as both compete for obesity prescriptions, though Novo Nordisk operates a much broader GLP-1-focused portfolio at significantly greater scale.
• Eli Lilly: Markets Zepbound (tirzepatide) and Mounjaro for obesity and diabetes. Comparable as a major competitor in the U.S. obesity market where Currax positions CONTRAVE as an oral alternative, with Eli Lilly pursuing a much broader metabolic disease franchise.
• Pfizer: Large-cap pharmaceutical company developing oral GLP-1 candidates (danuglipron) for obesity. Comparable as it competes in the obesity space where Currax operates, and represents a potential entrant into the oral obesity segment where Currax currently leads.
• Mallinckrodt Pharmaceuticals: Specialty pharmaceutical company focused on branded and generic therapies across multiple therapeutic areas including neurology and pain. Comparable as a specialty pharma acquirer and commercializer of niche prescription products with a similar product-portfolio model to Currax.
• Bausch Health: Specialty pharmaceutical company with branded, generic, and OTC products across multiple therapeutic areas. Comparable as a specialty pharma acquirer/commercializer that targets niche prescription assets, similar to Currax's business model of acquiring and growing specialty brands.
• Amneal Pharmaceuticals: Generic and specialty pharmaceutical company with branded and authorized generic products including CNS and migraine therapies. Comparable as a specialty pharma company operating in migraine and CNS (Currax markets TREXIMET and ONZETRA Xsail for migraine, and SILENOR for sleep).
• Roche: Global pharmaceutical company developing oral GLP-1 obesity candidates through its Genentech subsidiary. Comparable as an emerging oral obesity competitor with significantly greater R&D and commercial resources than Currax.
• Endo International: Specialty pharmaceutical company with branded and generic products in CNS, migraine, and pain. Comparable as a specialty pharma operator with similar therapeutic area overlap (migraine, sleep) and a comparable acquisition-and-commercialize business model.

Direct peers

• Vivus: Specialty pharmaceutical company marketing Qsymia (phentermine/topiramate), another oral chronic weight management therapy. Comparable as a direct competitor in the oral obesity medication segment with similar specialty pharma commercial model and target patient population.

Emerging players

• Hims & Hers Health: DTC telehealth platform offering prescription weight loss treatments including compounded and branded therapies. Comparable as a direct-to-consumer channel competing for the same cash-pay obesity patients Currax targets via CurAccess and GoodRx programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?v=cUnt5zq7X18
• LinkedInlinkedin.com/company/currax-pharmaceuticals-llc

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Currax Pharmaceuticals